MarketPeel
Insider Trading Intelligence
Pricing
…
AC

Abraham Ceesay

PCRX
DIRECTOR · PACIRA BIOSCIENCES, INC. · CIK 0001722140
FILING MIX · LIFETIME29%/71%
BUYS
11
SELLS
27
TOTAL VALUE
$4.55M
COMPANIES
3
ACTIVE SINCE
Oct 2023
HOLDINGS NOW
559,450
AVG SELL PX
$27.46
TRADE KIND
SHOWING 38 / 38
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
25 backtested trades · 8 horizons · 56 pending
Forward-return performance of every backtestable P/S trade by Abraham Ceesay, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d25+16.00%+4.81%+1.29%+3.52%+2.42%—
14d25+4.00%+6.54%+1.68%+4.86%+4.22%—
30d25+76.00%-1.17%+0.48%-1.65%-5.77%—
60d25+44.00%+6.12%+1.92%+4.20%+2.87%—
90d25+28.00%+12.47%+3.42%+9.05%+8.81%—
180d25(6 pending)+5.26%+25.60%+6.96%+18.64%+12.71%—
1y25(25 pending)——————
2y25(25 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PCRX · 9,039 shares · as of Sep 4, 2025
07,74215,48423,22530,96720242025SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 11 buys / 27 sellsCOVERAGE · 11 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
876$40.34$35.3K548,027Jun 29, 2026Jul 1, 2026 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,344$39.77$292.1K548,903Jun 29, 2026Jul 1, 2026 ↗View →
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
PURCHASEGRANT
Stock grant
1,438$177.62$255.4K2,384May 8, 2026May 11, 2026 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,281$29.80$68.0K556,247Feb 18, 2026Feb 19, 2026 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,983$29.04$86.6K22,829Feb 18, 2026Feb 19, 2026 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,100$29.80$62.6K20,729Feb 18, 2026Feb 19, 2026 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,552$29.05$103.2K558,528Feb 18, 2026Feb 19, 2026 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
428,000——428,000Feb 2, 2026Feb 4, 2026 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,833$26.12$152.3K562,080Jan 20, 2026Jan 22, 2026 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,083$26.11$132.7K25,812Jan 20, 2026Jan 22, 2026 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,147$28.84$61.9K33,831Dec 17, 2025Dec 18, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,421$30.04$72.7K31,410Dec 17, 2025Dec 18, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,441$28.84$70.4K571,305Dec 17, 2025Dec 18, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,792$30.04$83.9K568,513Dec 17, 2025Dec 18, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
515$31.04$16.0K30,895Dec 17, 2025Dec 18, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
600$31.04$18.6K567,913Dec 17, 2025Dec 18, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,242$24.91$55.8K38,819Nov 17, 2025Nov 18, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,777$24.92$69.2K576,802Nov 17, 2025Nov 18, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,841$25.44$72.3K35,978Nov 17, 2025Nov 18, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,056$25.43$77.7K573,746Nov 17, 2025Nov 18, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
755$26.17$19.8K41,061Oct 15, 2025Oct 16, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,328$25.75$111.4K41,816Oct 15, 2025Oct 16, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,186$26.14$31.0K579,579Oct 15, 2025Oct 16, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,647$25.72$119.5K580,765Oct 15, 2025Oct 16, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
700$27.04$18.9K46,144Sep 17, 2025Sep 19, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,400$26.87$37.6K585,412Sep 17, 2025Sep 19, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
34,885$26.30$917.5K46,844Sep 17, 2025Sep 19, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
39,435$26.30$1.04M586,812Sep 17, 2025Sep 19, 2025 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
2,354$27.19$64.0K9,039Sep 4, 2025Sep 8, 2025 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
6,163——11,393Jun 11, 2025Jun 13, 2025 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
11,279——11,279Jun 11, 2025Jun 13, 2025 ↗View →
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
PURCHASEGRANT
Stock grant
2,082$135.04$281.2K2,082Jun 2, 2025Jun 3, 2025 ↗View →
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
PURCHASEGRANT
Stock grant
946$135.04$127.7K946Jun 2, 2025Jun 3, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
428,000——428,000Feb 3, 2025Feb 4, 2025 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
12,179——12,179Jun 12, 2024Jun 13, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
5,230——5,230Jun 12, 2024Jun 13, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
530,647——530,647Jun 6, 2024Jun 10, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
30,967——30,967Oct 6, 2023Oct 11, 2023 ↗View →
Other insiders · PCRX
Loading peer insiders…
About this filer
CIK 0001722140
ROLE
Director
PRIMARY
PCRX
COMPANIES
3
ACTIVE SINCE
Oct 2023
MARKETPEEL · /INSIDER/0001722140DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback